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ABSTRACT
Introduction
The effects of SARS-CoV-2 in pregnancy not fully delineated. We will describe the 
incidence of COVID-19 in pregnancy at population level in Scotland, in a prospective cohort 
study using linked data.  We will determine associations between COVID-19 and adverse 
pregnancy, neonatal and maternal outcomes; and the proportion of confirmed cases of SARS-
CoV-2 infection in neonates associated with maternal COVID-19.
Methods and analysis
Prospective cohort study using national linked datasets. We will include all women in 
Scotland, UK, who were pregnant on, or became pregnant after, 1st March 2020 (the date of 
the first confirmed case of SARS-CoV-2 infection in Scotland), and all births in Scotland 
from 1st March 2020 onwards. Individual-level data will be extracted from datasets 
containing details of all livebirths, stillbirth, terminations of pregnancy, and miscarriages and 
ectopic pregnancies treated in hospital or attending general practice. Records will be linked 
within the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) 
platform, which includes primary care records, virology and serology results, and details of 
COVID-19 Community Hubs and Assessment Centre contacts and deaths. We will perform 
analyses using definitions for confirmed, probable and possible COVID-19, and report 
serology results (where available). Outcomes will include congenital anomaly, miscarriage, 
stillbirth, termination of pregnancy, preterm birth, neonatal infection, severe maternal disease 
and maternal deaths. We will perform descriptive analyses and appropriate modelling, 
adjusting for demographic and pregnancy characteristics, and the presence of co-morbidities. 
The cohort will provide a platform for future studies of the effectiveness and safety of 
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4
therapeutic interventions and immunisations for COVID-19, and their effects on childhood 
and developmental outcomes. 
Ethics and dissemination
COPS is a sub-study of EAVE II, which has approval from the National Research Ethics 
Service Committee. Findings will be reported to Scottish Government, Public Health 
Scotland and published in peer reviewed journals. 
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ARTICLE SUMMARY
Strengths and limitations of this study
 We will interrogate Scottish national data at the population level to provide 
information on the incidence of, and outcomes following, COVID-19 outcomes in 
pregnant women.
 We are expanding an existing national pandemic reporting platform (EAVE II) to 
include assessment of all pregnancy outcomes. EAVE II uses de-identified individual 
patient-level data for almost the entire population of Scotland from general practices, 
hospitals, death registry, virology (Reverse Transcriptase Polymerase Chain Reaction; 
RT-PCR) and serology tests to investigate the epidemiology of COVID-19. 
 This is an observational study and residual confounding is a potential concern. 
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INTRODUCTION
The effects of novel Severe Acute Respiratory Syndrome Coronavirus -2  (SARS-CoV-2) in 
pregnancy are yet to be fully delineated.1 Pregnant women are at greater risk of complications 
and severe disease from infection with other coronaviruses including SARS and Middle 
Eastern Respiratory Syndrome (MERS).2 3 Pregnant women were thus identified as a 
potential vulnerable group in some countries and advised to take additional precautions as the 
Coronavirus Disease 2019 (COVID-19) pandemic unfolded.2 3 4 
To inform public health policy, it is crucial to determine the effects of SARS-CoV-2 infection 
on maternal, pregnancy, and neonatal health. SARS-CoV-2 transmission from mother to baby 
(antenatally or intrapartum) appears to be possible,5 but the proportion of pregnancies 
affected and the clinical significance is uncertain.  Potential effects of the virus on 
miscarriage, congenital anomalies, fetal growth, timing of delivery, and stillbirth are 
unknown.  We know from other viral infections in pregnancy that infections with mild 
maternal symptomatology can have substantial impacts on the developing fetus (e.g. 
Cytomegalovirus, Parvovirus, Zika virus),6 although mechanisms of placental transmission of 
virus vary.7  The canonical receptors for SARS-CoV-2 (the angiotensin- converting enzyme 2 
[ACE2] receptor and the serine protease TMPRSS2) are not co-expressed in the placenta, 
making placental infection unlikely.8 9 Nevertheless, case reports have shown evidence 
suggestive of viral infection of the placenta, in association with pregnancy complications 
such as pre-eclampsia and abruption10 and second trimester miscarriage.11 Reports that 
include neonatal test results for SARS-CoV-2 show positive cases only in a minority of 
babies, with significant respiratory disease being rare in neonates.12 However, some babies 
born to mothers who had COVID-19 have increased concentrations of both immunoglobulin 
IgM and IgG for SARS-CoV-2.13 14 As IgM cannot cross the placenta, neonatal circulating 
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SARS-CoV-2 IgM indicates vertical transmission of virus, although all the infants in reports 
so far have been asymptomatic and tested negative for SARS-CoV-2 viral RNA at birth.13 14 
There are also plausible links between SARS-CoV-2 and pregnancy complications such as 
preterm birth, which may be mediated either as a manifestation of COVID-19 disease itself; 
or indirectly through increased stress due to the pandemic and containment measures, or 
through altered physician threshold for iatrogenic preterm delivery in women with infection.1
Understanding the effects of COVD-19 at different stages in pregnancy and perinatally will 
help inform policy on shielding strategies, and advice to pregnant women and those 
considering pregnancy.  It is also essential to inform immunisation strategies when vaccines 
are available. For example, immunisation in early pregnancy may help protect against 
maternal infection during pregnancy and reduce complications; but immunisation in later 
pregnancy may be preferential to provide passive immunisation to babies if neonatal 
infection is the predominant concern.
There are a number of surveillance studies gathering data on pregnant women with COVID-
19 currently underway in the UK, summarised in Table 1. 
Collectively, these surveillance studies can provide detailed characterisation of selected 
groups of pregnant women (and neonates) affected by COVID-19.  The study outlined in this 
protocol will complement these existing studies by providing population-based information 
(for the whole of Scotland) on the risks of, and outcomes following, COVID-19 at any stage 
of pregnancy for women in the community and/or admitted to hospital.
The primary objectives of the COVID-19 in Pregnancy in Scotland (COPS) study are to: 
a)  describe the incidence of SARS-CoV-2 infection and COVID-19, in the pregnant 
population;
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b) determine associations between COVID-19 and adverse maternal, pregnancy, and neonatal 
outcomes;
c) determine the proportion of neonates with confirmed SARS-CoV-2 infection that are 
associated with COVID-19 in the baby’s mother
Secondary objectives are to:
a) assess the proportion of COVID-19 cases in pregnant women and neonates who are 
included in relevant other enhanced surveillance studies (e.g. BPSU, CO-CIN);15-17
b)  provide a platform to assess the safety and effectiveness of any new or existing 
prophylactic or therapeutic interventions (e.g. new or repurposed therapies, vaccines, 
antimicrobials) in pregnant women and their babies;
c) enable evaluation of the longer-term sequelae of maternal SARS-CoV-2, and therapeutic 
interventions to mitigate SARS-CoV-2 in pregnancy and in children.
This COPS study is a sub-study of the EAVE II study (Early Pandemic Evaluation and 
Enhanced Surveillance of COVID-19 observational study using linked Scottish national 
data).18-20 EAVE II is a national, real-time, data platform to identify the population groups 
most at risk from SARS-CoV-2 infection and COVID-19 disease and mortality, linking 
Scottish General Practice (GP) records (5.4 million registered patients) with secondary care 
and laboratory datasets.18  Pregnancy will be assessed as one of these at-risk groups.  Within 
this COPS study protocol, we specify in detail the national datasets that will be incorporated 
within the EAVE II platform to enable pregnant women (and associated pregnancy start and 
end dates) to be reliably identified. We also specify in detail the maternal, pregnancy and 
neonatal outcomes following maternal COVID-19 that will be examined.
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METHODS
Patient and public involvement
Parents and pregnant women have not been involved in design of this protocol. However, we 
will work in partnership with a patient and public involvement group set up for the EAVE II 
study regarding interpretation of results, presentation and dissemination of findings. We also 
have close links with Tommy’s charity who will co-develop dissemination plans and help 
ensure that findings reach relevant stakeholders.
Study design and population
This is a prospective cohort study using national maternity, community, hospital and 
laboratory linked datasets, in Scotland, UK. We will include all women in Scotland who were 
pregnant on, or became pregnant after 1st March 2020 (the date of the first confirmed case of 
SARS-CoV-2 infection in Scotland21), and all live born babies born in Scotland from 1st 
March 2020 onwards. The end date for the study will be determined by the future 
development, and in particular suppression of, the pandemic in Scotland. 
Women in the cohort with the earliest dates of conception will only have been at risk of 
COVID-19 at the very end of their pregnancy.  Women with more recent dates of conception 
will have been at risk for longer, up to women with date of conception from 1 March 2020 
onwards who will be at risk from conception onwards (until viral transmission is completely 
suppressed).
We aim to use a dynamic cohort of the entire pregnant population; therefore, selection bias is 
not anticipated and the dataset will be fully generalisable to Scotland (with extensive 
generalisability to other high-income nations).
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Databases
Individual-level data will be extracted from the datasets listed below. Records relating to the 
same individual will be linked deterministically using the Community Health Index (CHI) 
number.22 The CHI number is a unique identifier provided by National Health Service (NHS) 
Scotland for each resident registered with a general practice. Public Health Scotland routinely 
adds both maternal and baby CHI numbers to live birth registration records: these ‘spine’ 
records will be used to facilitate intergenerational linkage of records relating to mothers and 
their babies.
An overall schema for the planned linkage is provided in Figure 1. Unless otherwise specified, 
included datasets are held by Public Health Scotland (PHS) and PHS is the data controller.
Datasets to identify pregnant women in the general population and associated pregnancy 
start and end dates, and pregnancy and neonatal outcomes
i) Antenatal booking records: This is a new national data return developed as part of the 
response to the COVID-19 pandemic providing information on all women booking for 
antenatal care with NHS maternity services throughout Scotland. It will be used for 
identification of women with ongoing pregnancies in near real-time. All other records 
identify end of pregnancy events, thus there is a time-lag before records are generated. More 
than 99% of births in Scotland book for antenatal care with NHS maternity services.23
ii) Abortion Act Scotland [AAS] records: These are statutory notifications of termination of 
pregnancy, and will be used to identify all terminations of pregnancy, and including 
terminations of pregnancy indicated by congenital anomaly.24 
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iii) National Records of Scotland (NRS) statutory stillbirth registrations: Scottish legislation 
requires all stillbirths at 24 weeks gestation or more to be registered with NRS.25
iv) NRS statutory live birth registrations: Scottish legislation requires all live births at any 
gestation to be registered with NRS.26
v) NHS Scottish health board live births: A new national data return developed as part of the 
response to the COVID-19 pandemic (specifically to mitigate unavailability of NRS statutory 
live birth registration records when registration processes were suspended) providing 
information on all live births notified by maternity services to NHS Board child health 
administrative departments. 
vi) GP data: Data from all patients registered in general practices are included in the EAVE II 
platform.18 In COPS, these records will be used for identification of women with early 
miscarriage or ectopic pregnancy not managed in hospitals, and potential confounding co-
morbidities.
vii) Scottish Morbidity Record (SMR) 01: The SMR01 database includes all general day case 
and in-patient admissions in Scotland.27 Admissions to neonatal, maternity, and mental health 
care are excluded from SMR01 as they are covered by other specialist datasets.  SMR01 
records are included in the EAVE II platform, and in COPS will be used for identification of 
women with early miscarriage or ectopic pregnancy managed in hospitals, and potential 
confounding co-morbidities. 
viii) SMR 02: The SMR02 database includes all day case and in-patient admissions to 
maternity specialties in Scotland.27 It will be used for identification of later miscarriage, 
stillbirth, and live births managed in maternity units (≥98% of births in Scotland) and some 
home births (≤2% of births in Scotland).23 
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ix) Scottish Birth Record (SBR): The SBR records basic demographic data on all births in 
Scotland, and additional clinical information and diagnostic and operational procedure codes 
on babies admitted to neonatal care.28 It will be used to identify neonates admitted to neonatal 
care. 
x) Scottish Intensive Care Society Audit Group (SICSAG) records: This is a national 
database of patients admitted to adult general critical care units in Scotland detailing 
information on the management of critically ill or injured patients. All general Intensive Care 
Units and combined ICU/High Dependency Units (HDU) collect data and more than 90% of 
general High Dependency Units and a number of specialist ICU and HDUs also provide 
records.29 In COPS these will be used to identify women admitted to critical care with 
COVID-19.
Datasets to identify women with confirmed SARS-CoV-2 infection or COVID-19
i)  Electronic Communication of Surveillance in Scotland (ECOSS)30 and other viral RT-PCR 
and serology results held separately by PHS are included on the EAVE II platform.18 In 
COPS, these will be used for identification of pregnant women and neonates with positive 
viral RT-PCR and serology, and women with negative viral RT-PCR. 
ECOSS is a database that holds surveillance data on various microorganisms (e.g. influenza 
virus, coronavirus) and infections reported from NHS diagnostic and reference laboratories.30 
Data on laboratory results for all SARS-CoV-2 RT-PCR tests carried out in Scotland are 
being collated by ECOSS and can be linked to other data sources.30 
In sub-studies, residual sera from routine antenatal booking blood tests and 28 week gestation 
blood group and red cell antibody screen samples will be tested for SARS-CoV-2 antibodies.  
Residual sera from other blood tests conducted as part of routine (not COVID-19 related) 
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primary and secondary care, and blood donation, are also being tested for SARS-CoV-2 
antibodies as part of the surveillance of the pandemic in Scotland, and any results relating to 
pregnant women will also be incorporated.31  Results from these sub-studies will be linked to 
pregnancy records and used to determine exposure to SARS-CoV-2 by the presence of 
antibodies.18
ii) GP consultations, GP out of hours attendances, NHS24 calls, COVID-19 phone 
assessment hub calls, and COVID-19 clinical assessment centre attendances are linked on the 
EAVE II platform.18 We will extract data on pregnant women with possible COVID-19 from 
GP records and a network of COVID-19 Community Hubs and Assessment Centres 
established by NHS Health Boards across Scotland. These provide a direct and rapid route for 
people with COVID-19 symptoms that have worsened or not improved after a week to seek 
advice and primary care. The pathway for management of patients in the community with 
symptoms suggestive of COVID-19 has evolved as the pandemic has progressed.  In early 
March 2020, patients with symptoms were advised to phone their GP in hours or NHS 24 out 
of hours for advice.  Patients requiring face to face assessment were then seen in GP surgeries 
or GP out of hours centres.  On 17 March 2020, the Scottish Government published details of 
a new national patient pathway, whereby all patients with symptoms (in or out of hours) were 
encouraged call NHS 24 as the initial point of contact.32 Patients thought likely to have 
COVID-19 were then passed to a new, dedicated NHS24 COVID-19 phone assessment hub.  
Those requiring face-to-face assessment in general were then seen in (or visited at home by 
staff from) an NHS24 COVID-19 clinical assessment centre, although pregnant women could 
alternatively be directed to their maternity service triage base.32 
iii) Unscheduled Care Datamart (UCD):  This links data from NHS 24, Scottish Ambulance 
Service, Out of Hours Primary Care, Emergency Department, Acute and Mental Health 
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admissions and Deaths to show a Continuous Unscheduled Care Pathway. Data is included in 
the EAVE II platform.18 In COPS, we will use Scottish Ambulance Service incident and 
A&E attendance records for identification of women with possible COVID-19.33
iv) NRS statutory death registrations will be used for identification of any women with 
COVID-19 recorded as cause of death.34
v) SMR01, SMR02, and NRS stillbirths will be used to identify women with COVID-19 
recorded as cause of admission/stillbirth.25 27
Datasets recording treatments, vaccination, shielding status and inclusion in other studies
i) Prescribing Information System (PIS). This includes information on all prescribed 
medications that are dispensed in the community in Scotland.35 Lookback records are 
included in the EAVE II platform18 and used to provide information on the presence of co-
morbidities. In COPS records will also be used provide information on COVID-19 treatments 
given. 
ii)  Scottish Hospital Electronic Prescribing and Medicines Administration (HEPMA) 
systems are currently available within four Scottish hospitals, and data from these are linked 
in the EAVE II platform18 to provide data on medications for COVID-19 administered in 
hospitals.36
iii) GP consultation records included on the EAVE II platform18 will be used to extract 
information on vaccinations for SARS-CoV-2 and other viruses.
iv) We will identify pregnant women and neonates with COVID-19 in existing enhanced 
surveillance studies using minimal ‘flag’ variables from the BPSU and CO-CIN studies,15-17 
as well as other trials who can provide this data. 
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Exposure and Outcome definitions 
Pregnancy, start and end dates and pregnancy outcomes
A pregnancy will be defined by presence of a record pertaining to a pregnancy. As well as 
identifying completed pregnancies, through a record of any pregnancy outcome, we will be 
able to identify ongoing pregnancies at population level, through inclusion of records from 
women booked for antenatal care. 
The following definitions will be used for pregnancy outcomes. The codes and data sources 
used to identify relevant records, are described in detail in Supplementary material. 
i) Ectopic pregnancy: This will include any early pregnancy loss where the pregnancy is 
implanted outwith the uterus 
ii) Spontaneous pregnancy losses: These will be defined as miscarriage at less than 20 weeks 
gestation, late fetal losses at 20 - 23 weeks if there are no signs of life; and stillbirth if birth 
occurs at 24 weeks’ gestation or more and there are no signs of life. If numbers allow, the 
miscarriages will be further split into the more clinically meaningful outcome categories of 
miscarriage at less than 14 weeks gestation; and miscarriage 14 weeks gestation and beyond. 
iii) Termination of pregnancy: These will be subclassified by the grounds for termination of 
pregnancy of the Abortion Act 1967.37
iv) Live birth: The birth of a baby at any gestation with signs of life. No lower gestational 
limit will be used although in practice around 22 weeks gestation would be considered the 
lower limit at which live born babies may survive
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Pregnancy start date will be taken as the date of conception. In pregnancies that have ended 
date of conception will be imputed from
 “Date of conception = pregnancy end date - (the number of weeks of gestation at pregnancy 
end + 2 weeks)”
In ongoing pregnancies that have booked with maternity services and have a documented 
estimated date of delivery (EDD), date of conception will be imputed from 
“Date of conception = date of antenatal booking – (gestation at booking + 2 week)” 
In ongoing pregnancies without a documented EDD, date of conception will be imputed from 
“Date of conception = date of last menstrual period + 2 weeks”.
It is standard care for women who book with maternity services in Scotland have a first 
trimester ultrasound scan (usually 11-13+6 weeks gestation) to determine EDD, from which 
gestation is calculated. Booking takes place around 10 weeks gestation. 
SARS-CoV-2 infection and COVID-19
We will use the following definitions for COVID-19. 
 Confirmed COVID-19 in pregnancy will be defined as positive viral PCR for SARS-
CoV-2 on a test. 
 Probable COVID-19 will be defined as COVID-19 recorded on a hospital admission, 
stillbirth, or a maternal death record (using ICD10 codes U07.1, U07.2, B34.2, B97.2)
 Possible COVID-19 will be defined as meeting one or more of the following criteria:
o GP consultation or GP out of hours attendance coded as possible COVID-19
o NHS24 call coded as possible COVID-19
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o Patient triaged to NHS24 COVID-19 phone assessment hub or clinical 
assessment centre
o Scottish Ambulance Service call for possible COVID-19
o A&E attendance coded as possible COVID-19
o Negative SARS-CoV-2 viral PCR test when the test was taken for clinical 
indications (i.e. excluding tests taken for routine testing of asymptomatic 
individuals)
The above definitions are hierarchical, e.g. a positive SARS-CoV-2 nucleic acid test assigns a 
woman to the confirmed COVID-19 group, regardless of the presence of other records.
We will use the indication for SARS-CoV-2 nucleic acid test, which is recorded in ECOSS 
records, to distinguish between tests taken for clinical indications and routine testing of 
asymptomatic individuals. If we can’t distinguish between these groups, we will exclude 
women testing negative from both the ‘case’ and ‘control’ groups – and base our definition of 
possible case on presentation to various healthcare settings with relevant symptoms as 
described above.
SARS-CoV-2 infections during pregnancy will be identified if the event of interest (e.g. 
SARS-CoV-2 nucleic acid test taken, admission, unscheduled care attendance) occurs 
between 14 days prior to the estimated date of conception (to include women who could be 
viraemic periconceptually) and the end of pregnancy.
We will seek to access serological data as these become available. We will report the 
proportion of women with circulating IgG and/or IgM for SARS-CoV-2 and may incorporate 
serology results in case definitions and/or use in additional analyses as data mature. The 
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timing of exposure to/infection with SARS-CoV-2 is more difficult to ascertain from 
serology results than from the other indicators of (possible) infection listed above.  Dates of 
serological testing; start and end of pregnancy; and plausible start (and, if applicable, end) of 
transmission of SARS-CoV-2 in Scotland will be taken into account when identifying women 
with exposure before, during, and after pregnancy. Seroconversion windows will also be 
considered for women with sequential serology results.
We have included hierarchical definitions of COVID-19 to mitigate against potential biases 
that may results from i) limitations of diagnostic strategy performance and ii) variation in 
availability of diagnostic tests. The definition of confirmed COVID-19 (women who test 
positive on PCR) may potentially bias results away from the null hypothesis (due to false 
negative PCR results). The definition of possible COVID-19 may potentially bias results 
towards the null hypothesis (due to false positive ‘diagnoses’). We will test our hypotheses in 
this observational cohort across the range of assumptions allowed by hierarchical definitions. 
Other diagnostic and exposure categories may be added as the pandemic develops and 
diagnostic criteria change. 
Fetal and neonatal outcomes
The following fetal and neonatal outcomes will be included.
i) Congenital anomaly (major structural anomaly as defined by EUROCAT 38 diagnosed in 
any pregnancy terminated at any gestation due to anomaly; miscarriage or stillbirth at ≥20 
weeks; or live born baby diagnosed at <28 days of age)
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ii) Preterm birth (<37 weeks) categorised as spontaneous or medically indicated (i.e. 
following induction of labour or elective Caesarean section undertaken to mitigate clinical 
risk)
iii) Small for gestational age (birthweight <10th centile by WHO-UK90 growth reference 39)
iv) Admission to neonatal care
v) Neonatal SARS-CoV-2 infection (currently defined as positive viral RT-PCR test on 
sample taken from baby aged 0-27 days, definition may be expanded to include results of 
serology tests as evidence and testing options accumulate)
vi) Neonatal mortality (death of a live born baby at <28 days of age)
vii) Extended perinatal mortality (stillbirth or neonatal mortality) 
Maternal outcomes
We will collect data on the following maternal outcomes:
 COVID-19 disease requiring any hospital admission (defined as a patient admitted 
within 14 days of confirmed or probable COVID-19, or with confirmed or probable 
COVID-19 during admission)
 Severe COVID-19 disease requiring critical care admission or resulting in death 
(defined as patient admitted to critical care or dying within 28 days of confirmed or 
probable COVID-19, or with confirmed or probable COVID-19 during hospital 
admission, regardless of recorded cause of death)
 Any maternal death (defined as the death of a woman while pregnant or within 42 
days of the termination of pregnancy, irrespective of the duration and site of the 
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pregnancy, from any cause related to or aggravated by the pregnancy or its 
management but not from accidental or incidental causes)
Population characteristics and confounding factors
A number of maternal and pregnancy characteristics will be collected that could be potential 
confounders or effect modifiers. 
i) Demographics including age band and socioeconomic status determined by the Scottish 
Index of Multiple Deprivation (SIMD) classification of material deprivation.40 SIMD 
Quintiles 1 through 5 refer to the small geographical areas (data zones) each containing 20% 
of the Scottish population, with quintile 1 indicating the most deprived areas. The SIMD is a 
combination of 38 indicators of the following seven domains: income, employment, health, 
education, housing, geographical access to services, and crime. We will also include 
urban/rural status of maternal residence based on the urban/rural 8 fold classification (UR8)41 
where 1 is assigned to large urban areas and 8 is assigned to remote rural areas. We recognise 
ethnicity to be a complex indicator variable related to sociodemographic factors, health 
systems use, pregnancy and health outcomes and genetics. We will explore the possibility of 
including self-reported maternal ethnicity although missing data may preclude this.
ii) Clinical at-risk groups of individuals with certain underlying medical conditions thought 
to increase risk of COVID-related complications. The following clinical at-risk conditions are 
identified in the EAVE II platform18: a) chronic respiratory disease; b) chronic heart disease; 
c) chronic liver disease; d) chronic kidney disease; e) chronic liver disease; f) chronic 
neurological disease; g) Diabetes; h) Conditions or medications causing impaired immune 
function; i) Asplenia or dysfunction of spleen and j) body mass index (BMI). In addition, we 
will link pregnancy records with the shielded patient list included in the EAVE II platform 
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(those with extremely high risk of severe manifestation of SARS-CoV-2 infection, and hence 
advised by Scottish Government to ‘shield’ during the pandemic). We will re-categorise 
clinical risks for the pregnant population as i) Diabetes (Type I; Type II; Other pre-
pregnancy; Gestational Diabetes); ii) clinically vulnerable risk group (for whom seasonal 
influenza vaccination is recommended outwith pregnancy); iii) clinically extremely 
vulnerable risk group ( those advised to ‘shield’ during the pandemic);42 and iv) no clinical 
at-risk condition. BMI, which can be associated with adverse pregnancy outcomes as well as 
COVID-disease will be included separately, with pre-pregnancy BMI or BMI at antenatal 
booking categorised as Underweight, Normal, Overweight, Obese and Severely Obese 
according to WHO definitions.43 Other categorisation will be considered depending on 
numbers of pregnant women with these conditions, and emergence of patterns of risk for 
COVID-19 disease.
iii) Smoking status in pregnancy will be presented into the following four categories: Current 
smoker, non-smoker, ex-smoker and not recorded. Smoking status will be taken from 
booking record and/or GP records.
iv) Obstetric characteristics (SMR02) will include previous pregnancies, plurality (number of 
babies), drug and alcohol use, antenatal steroid administration, mode of birth or management 
of pregnancy loss.
v) Clustering of outcomes by the 14 different Maternal NHS Board areas of residence. 
Statistical analysis
General Approach
Baseline characteristics of all study participants will be described in relation to presence and 
absence of confirmed, probable or possible COVID-19 and outcomes of interest. Mean, median 
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and proportions, together with a measure of dispersion will be provided where appropriate to 
describe differences between the various groups of interest based on the nature of each variable. 
Missing data will be provided for each variable. Two-tailed hypotheses tests will be used for 
all study’s outcomes, with 95% confidence intervals presented to show precision of estimates, 
and p values reported. All analyses will be carried out using the R statistical programming 
language. We do not propose to make any formal statistical adjustment for the multiple 
comparisons as the principal aim of the study is to estimate the effect of COVID-19 infection 
on pregnancy outcomes.   The estimated effects and 95% confidence intervals will be reported 
for the range of outcomes.  However, a caveat will be clearly expressed regarding the dangers 
of over interpreting these data, given the multiple outcomes used, particularly if it transpires 
that conflicting results are obtained from the differing outcome measures. The approach to 
imputing estimated date of conception when gestation is missing on records indicating 
pregnancy status is detailed in Supplementary material 1. Missing data are otherwise not 
anticipated to be a substantial problem (and hence imputation techniques are not anticipated) 
but this will be confirmed once initial data extracts are available, and our approach to handling 
missing data will be confirmed prior to analysis.
Analyses will be updated monthly, providing results for sequential months, and also 
information on the cumulative risk of COVID-19 as women progress through their 
pregnancies. Simple smoothing techniques such as rolling averages will be used to facilitate 
presentation and interpretation of findings. We will also present our results as proportions of 
COVID-19 infection, together with confidence intervals based upon the Wilson method.  We 
will describe the temporal changes in the proportion using cumulative risk models.  
Covariates such as the trimester of pregnancy, age of the mother and deprivation will also be 
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included with a view to estimating the potential effects of these variables on the risk of 
COVID-19 infection
If/when numbers of cases allow, we will examine incidence of COVID-19, and report 
outcomes, in subgroups including by maternal age band, SIMD deprivation quintile, maternal 
NHS Board area of residence and maternal comorbidity status. We may assess whether 
findings are robust to more stringent or emerging definitions of confirmed and suspected 
infection, in sensitivity analyses. Other sensitivity and subgroup analyses may be indicated 
by initial findings. We will clearly state which analyses were pre-specified and which were 
post-hoc.
Incidence of SARS-CoV-2 and COVID-19 in the pregnant population 
We will perform descriptive analysis of the number of cases over the total number of 
pregnancies i.e. how many pregnant women have had confirmed, probable or possible 
COVID-19/ total number of pregnant women.  Where timing of infection is known, we will 
describe incidence of SARS-CoV-2 infection by trimester of exposure - first trimester (0-13 
weeks gestation) second trimester (14-27 weeks gestation); third trimester (≥28 weeks 
gestation)44; with denominators consisting of ongoing pregnancies in each trimester. 
Associations between COVID-19 and adverse pregnancy, neonatal and maternal outcomes.
Initially we will perform a descriptive analysis comparing pregnancy outcomes in women 
with and without i) confirmed; ii) probable and iii) possible COVID-19. In order to create 
appropriate comparison groups, for each woman with COVID-19, we will identify ten 
women without COVID-19, with an ongoing pregnancy matched on gestation of diagnosis, 
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and additionally matched on maternal age and maternal deprivation level.  We will explore 
the need to match additional parameters such as NHS Board.
Occurrence of the outcomes of interest will be compared in women with and without 
COVID-19 using simple descriptive statistics (e.g. 95% confidence interval for the difference 
in proportions, generated using methods which accommodate proportions close to zero) and 
visualised appropriately.
If/when sufficient cases of COVID-19 among pregnant women accrue, and the univariable 
comparisons described above suggest that outcomes differ between women with and without 
SARS-2-CoV or COVID-19, formal modelling will be undertaken to quantify the impact of 
infection on outcomes, adjusting appropriately for confounding. We will use direct acyclical 
graphs (DAGs) to identify which factors to adjust for to mitigate for confounding.  
Appropriate methods that accommodate the competing risk and time to event nature of 
pregnancy outcomes (example event history analysis and/or multistate modelling) will be 
used.
Association of SARS-CoV-2 in neonates with maternal COVID-19
We will use summary statistics to describe neonatal SARS-CoV-2 (currently defined as 
positive viral PCR for SARS-CoV-2 on sample taken from a baby aged 0-27 days old) by 
presentation of COVID-19 in the mother in different time periods (apparent onset of maternal 
illness >14 days prior to birth; 14 days prior to birth - date of birth; day 1 - 13 following 
birth; day 14 - 27 following birth). 
Proportion of pregnant women and neonates with COVID-19 or SARS-CoV-2 that are 
included in relevant other enhanced surveillance studies (BPSU, CO-CIN)
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We will use summary statistics to describe the number and proportion of cases included in 
the external surveillance studies, and any factors associated with inclusion e.g. hospital 
admission status and NHS Board area of residence.
Creation of a platform to assess the safety and effectiveness of any new or existing 
prophylactic or therapeutic interventions and assessment of childhood outcomes after 
pregnancy exposure to COVID-19
We will use summary statistics to describe the treatments and prophylactic interventions used 
in pregnancy. We plan future linkage of data within COPS with child health and education 
data to allow assessment of long-term outcomes. 
Sample size
There are approximately 50,000 live births in Scotland per year, 13,000 terminations of 
pregnancy, 5,000 miscarriages managed in hospital and 200 stillbirths.  The estimated 
number of women in the population who are pregnant at any one time is approximately 
42,000.
We cannot influence the number of women with confirmed, probable or possible COVID-19 
available for analysis hence sample size calculations will not be performed.  We will report 
the precision with which we are able to estimate any association between COVID-19 and the 
outcomes of interest using confidence intervals as appropriate. An approximate estimate of 
the expected number of confirmed COVID-19 cases in pregnant women from March to May 
2020 is presented in Table 2. It is likely that there will be further confirmed or probable cases 
in pregnant women identified through PCR testing processed through UK Government 
laboratories and clinical diagnoses on discharge (or possibly stillbirth or maternal death) 
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records. In addition, it is likely that there will be considerably more possible cases among 
pregnant women based on the range of data sources listed above. 
ETHICS AND DISSEMINATION 
COPS is a sub-study of EAVE II, using unconsented data, which is covered by National 
Research Ethics Service Committee, South East Scotland 02 approval reference REC 
12/SS/0201: SA 2 and Public Benefit and Privacy Panel approval reference 2021-0116. 
Public Health Scotland and the Chief Medical Officer for Scotland are both (independent) 
data controllers for the national AAS database of termination of pregnancy notifications, thus 
the Chief Medical Officer has been informed of the intended use of AAS records for this 
study.
The results of monthly analyses summarising the incidence of COVID-19 in pregnant 
women, and outcomes seen in women with COVID-19 and pregnant controls, will be 
reported through the Public Health Scotland COVID-19 enhanced surveillance cell to the 
Scottish Government’s Chief Medical Officer’s COVID-19 Advisory Group.  Any results of 
formal modelling of outcomes that is undertaken will be reported through the same route.  
Results reported through this route may be provided as management information (i.e. without 
application of statistical disclosure control restrictions) as appropriate.
Results will also be submitted for peer reviewed academic publication and presented at 
international conferences.  All results put into the public domain will be subject to statistical 
disclosure control according to usual Public Health Scotland processes. Meta-data produced 
in this study will also become available to Health Data Research UK (HDRUK) Gateway. 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
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guidance45 and Reporting of studies Conducted using Observational Routinely-collected Data 
(RECORD) guidance46 will be used to guide transparent reporting.
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TABLES
Table 1: UK surveillance studies on COVID-19 in pregnant women and their babies
Name of study Institution Inclusion Reporting by Consent 
required
Likely 
coverage 
in 
Scotland
COVID-19 in 
Pregnancy 47
UK Obstetric 
Surveillance 
System study
(UKOSS) 
Any women 
admitted to 
hospital in the 
UK with 
confirmed 
COVID-19 at 
any stage of 
pregnancy
Front-line 
clinicians 
No High
Pregnancy And 
Neonatal 
outcomes for 
women with 
COVID-19 
(PAN-COVID) 
48
National 
Institute of 
Healthcare 
Research 
(NIHR) 
Imperial 
Biomedical 
Research 
Centre 
Women who 
have suspected 
or confirmed 
COVID-19 at 
any stage 
during 
pregnancy and 
their babies
Front-line 
clinicians
Yes Unknown 
as yet
Clinical 
Characterisation 
Protocol Tier 0 
The 
International 
Severe Acute 
Any patient 
admitted 
participating 
Reporting is by 
research nurses
No Low but 
may 
increase
Page 36 of 93
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
36
study (CO-CIN) 
17
Respiratory 
and 
emerging 
Infection 
Consortium 
(IASRIC)
hospitals in the 
UK with 
confirmed 
COVID-19
Neonatal 
complications of 
coronavirus 
disease 
(COVID-19) 17
British 
Paediatric 
Surveillance 
Unit (BPSU) 
All babies 
born to 
mothers with 
COVID-19 
who are 
admitted to 
neonatal care 
(whether the 
baby has 
COVID-19 or 
not) and all 
babies with 
confirmed 
COVID-19 in 
the neonatal 
period.
Front-line 
clinicians.  
No High
Multisystem 
inflammatory 
syndrome, 
Kawasaki 
disease and toxic 
British 
Paediatric 
Surveillance 
Unit (BPSU) 
All children 
less than 16 
years old 
(including 
neonates) with 
Front-line 
clinicians  
No High
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shock 
syndrome15
multisystem 
inflammatory 
syndrome due 
to SARS-CoV-
2 infection or 
otherwise 
unexplained. 
Understanding 
COVID-19 
infection in 
women and their 
babies 
(periCOVID)49
Public 
Health 
England and 
St George’s 
University 
London
Any pregnant 
woman with 
confirmed 
COVID-19 
infection from 
24 weeks 
gestation in 
England
Clinicians/research 
midwives and 
nurses
Yes None
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Table 2: Estimated number of confirmed COVID-19 cases March to May 2020 in 
pregnant women in Scotland
Total number of 
individuals testing 
positive (PCR) for 
SARS-CoV-2 (NHS 
labs only)
Women aged 15-44 
years testing 
positive (PCR) for 
SARS-CoV-2 (NHS 
labs only)
Estimated number of 
pregnant women 
testing positive 
(PCR) for SARS-
CoV-2 (NHS labs 
only)**
March 2020 ≈2000 ≈333* ≈17
April 2020 ≈9000 ≈1500* ≈75
May 2020 ≈4000 ≈667* ≈33
Total ≈15000 ≈2500 ≈125
* Assuming the distribution over time for this age/sex group is the same as for all tests,
as age/sex breakdown only available from published information50 for the total
** Assuming that around 5% of the female population aged 15-44 is pregnant at any one 
time, and that incidence of COVID-19 is the same in pregnant and non-pregnant women
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FIGURE LEGENDS
Figure 1: Overview of data linkage for the Covid-19 in Pregnancy in Scotland (COPS) study
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ABSTRACT
Introduction
The effects of SARS-CoV-2 in pregnancy not fully delineated. We will describe the 
incidence of COVID-19 in pregnancy at population level in Scotland, in a prospective cohort 
study using linked data.  We will determine associations between COVID-19 and adverse 
pregnancy, neonatal and maternal outcomes; and the proportion of confirmed cases of SARS-
CoV-2 infection in neonates associated with maternal COVID-19.
Methods and analysis
Prospective cohort study using national linked datasets. We will include all women in 
Scotland, UK, who were pregnant on, or became pregnant after, 1st March 2020 (the date of 
the first confirmed case of SARS-CoV-2 infection in Scotland), and all births in Scotland 
from 1st March 2020 onwards. Individual-level data will be extracted from datasets 
containing details of all livebirths, stillbirth, terminations of pregnancy, and miscarriages and 
ectopic pregnancies treated in hospital or attending general practice. Records will be linked 
within the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) 
platform, which includes primary care records, virology and serology results, and details of 
COVID-19 Community Hubs and Assessment Centre contacts and deaths. We will perform 
analyses using definitions for confirmed, probable and possible COVID-19, and report 
serology results (where available). Outcomes will include congenital anomaly, miscarriage, 
stillbirth, termination of pregnancy, preterm birth, neonatal infection, severe maternal disease 
and maternal deaths. We will perform descriptive analyses and appropriate modelling, 
adjusting for demographic and pregnancy characteristics, and the presence of co-morbidities. 
The cohort will provide a platform for future studies of the effectiveness and safety of 
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4
therapeutic interventions and immunisations for COVID-19, and their effects on childhood 
and developmental outcomes. 
Ethics and dissemination
COPS is a sub-study of EAVE II, which has approval from the National Research Ethics 
Service Committee. Findings will be reported to Scottish Government, Public Health 
Scotland and published in peer reviewed journals. 
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ARTICLE SUMMARY
Strengths and limitations of this study
 We will interrogate Scottish national data at the population level to provide 
information on the incidence of, and outcomes following, COVID-19 outcomes in 
pregnant women.
 We are expanding an existing national pandemic reporting platform (EAVE II) to 
include assessment of all pregnancy outcomes. EAVE II uses de-identified individual 
patient-level data for almost the entire population of Scotland from general practices, 
hospitals, death registry, virology (Reverse Transcriptase Polymerase Chain Reaction; 
RT-PCR) and serology tests to investigate the epidemiology of COVID-19. 
 This is an observational study and residual confounding is a potential concern. 
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INTRODUCTION
The effects of novel Severe Acute Respiratory Syndrome Coronavirus -2  (SARS-CoV-2) in 
pregnancy are yet to be fully delineated.1 Pregnant women are at greater risk of complications 
and severe disease from infection with other coronaviruses including SARS and Middle 
Eastern Respiratory Syndrome (MERS).2 3 Pregnant women were thus identified as a 
potential vulnerable group in some countries and advised to take additional precautions as the 
Coronavirus Disease 2019 (COVID-19) pandemic unfolded.2 3 4 
To inform public health policy, it is crucial to determine the effects of SARS-CoV-2 infection 
on maternal, pregnancy, and neonatal health. SARS-CoV-2 transmission from mother to baby 
(antenatally or intrapartum) appears to be possible,5 but the proportion of pregnancies 
affected and the clinical significance is uncertain.  Potential effects of the virus on 
miscarriage, congenital anomalies, fetal growth, timing of delivery, and stillbirth are 
unknown.  We know from other viral infections in pregnancy that infections with mild 
maternal symptomatology can have substantial impacts on the developing fetus (e.g. 
Cytomegalovirus, Parvovirus, Zika virus),6 although mechanisms of placental transmission of 
virus vary.7  The canonical receptors for SARS-CoV-2 (the angiotensin- converting enzyme 2 
[ACE2] receptor and the serine protease TMPRSS2) are not co-expressed in the placenta, 
making placental infection unlikely.8 9 Nevertheless, case reports have shown evidence 
suggestive of viral infection of the placenta, in association with pregnancy complications 
such as pre-eclampsia and abruption10 and second trimester miscarriage.11 Reports that 
include neonatal test results for SARS-CoV-2 show positive cases only in a minority of 
babies, with significant respiratory disease being rare in neonates.12 However, some babies 
born to mothers who had COVID-19 have increased concentrations of both immunoglobulin 
IgM and IgG for SARS-CoV-2.13 14 As IgM cannot cross the placenta, neonatal circulating 
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SARS-CoV-2 IgM indicates vertical transmission of virus, although all the infants in reports 
so far have been asymptomatic and tested negative for SARS-CoV-2 viral RNA at birth.13 14 
There are also plausible links between SARS-CoV-2 and pregnancy complications such as 
preterm birth, which may be mediated either as a manifestation of COVID-19 disease itself; 
or indirectly through increased stress due to the pandemic and containment measures, or 
through altered physician threshold for iatrogenic preterm delivery in women with infection.1
Understanding the effects of COVD-19 at different stages in pregnancy and perinatally will 
help inform policy on shielding strategies, and advice to pregnant women and those 
considering pregnancy.  It is also essential to inform immunisation strategies when vaccines 
are available. For example, immunisation in early pregnancy may help protect against 
maternal infection during pregnancy and reduce complications; but immunisation in later 
pregnancy may be preferential to provide passive immunisation to babies if neonatal 
infection is the predominant concern.
There are a number of surveillance studies gathering data on pregnant women with COVID-
19 currently underway in the UK, summarised in Table 1. 
Collectively, these surveillance studies can provide detailed characterisation of selected 
groups of pregnant women (and neonates) affected by COVID-19.  The study outlined in this 
protocol will complement these existing studies by providing population-based information 
(for the whole of Scotland) on the risks of, and outcomes following, COVID-19 at any stage 
of pregnancy for women in the community and/or admitted to hospital.
The primary objectives of the COVID-19 in Pregnancy in Scotland (COPS) study are to: 
a)  describe the incidence of SARS-CoV-2 infection and COVID-19, in the pregnant 
population;
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b) determine associations between COVID-19 and adverse maternal, pregnancy, and neonatal 
outcomes;
c) determine the proportion of neonates with confirmed SARS-CoV-2 infection that are 
associated with COVID-19 in the baby’s mother
Secondary objectives are to:
a) assess the proportion of COVID-19 cases in pregnant women and neonates who are 
included in relevant other enhanced surveillance studies (e.g. BPSU, CO-CIN);15-17
b)  provide a platform to assess the safety and effectiveness of any new or existing 
prophylactic or therapeutic interventions (e.g. new or repurposed therapies, vaccines, 
antimicrobials) in pregnant women and their babies;
c) enable evaluation of the longer-term sequelae of maternal SARS-CoV-2, and therapeutic 
interventions to mitigate SARS-CoV-2 in pregnancy and in children.
This COPS study is a sub-study of the EAVE II study (Early Pandemic Evaluation and 
Enhanced Surveillance of COVID-19 observational study using linked Scottish national 
data).18-20 EAVE II is a national, real-time, data platform to identify the population groups 
most at risk from SARS-CoV-2 infection and COVID-19 disease and mortality, linking 
Scottish General Practice (GP) records (5.4 million registered patients) with secondary care 
and laboratory datasets.18  Pregnancy will be assessed as one of these at-risk groups.  Within 
this COPS study protocol, we specify in detail the national datasets that will be incorporated 
within the EAVE II platform to enable pregnant women (and associated pregnancy start and 
end dates) to be reliably identified. We also specify in detail the maternal, pregnancy and 
neonatal outcomes following maternal COVID-19 that will be examined.
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METHODS
PATIENT AND PUBLIC INVOLVEMENTPatient and public involvement
Parents and pregnant women have not been involved in design of this protocol. However, we 
will work in partnership with a patient and public involvement group set up for the EAVE II 
study regarding interpretation of results, presentation and dissemination of findings. We also 
have close links with Tommy’s charity who will co-develop dissemination plans and help 
ensure that findings reach relevant stakeholders.
Study design and population
This is a prospective cohort study using national maternity, community, hospital and 
laboratory linked datasets, in Scotland, UK. We will include all women in Scotland who were 
pregnant on, or became pregnant after 1st March 2020 (the date of the first confirmed case of 
SARS-CoV-2 infection in Scotland21), and all live born babies born in Scotland from 1st 
March 2020 onwards. The end date for the study will be determined by the future 
development, and in particular suppression of, the pandemic in Scotland. 
Women in the cohort with the earliest dates of conception will only have been at risk of 
COVID-19 at the very end of their pregnancy.  Women with more recent dates of conception 
will have been at risk for longer, up to women with date of conception from 1 March 2020 
onwards who will be at risk from conception onwards (until viral transmission is completely 
suppressed).
We aim to use a dynamic cohort of the entire pregnant population; therefore, selection bias is 
not anticipated and the dataset will be fully generalisable to Scotland (with extensive 
generalisability to other high-income nations).
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Databases
Individual-level data will be extracted from the datasets listed below. Records relating to the 
same individual will be linked deterministically using the Community Health Index (CHI) 
number.22 The CHI number is a unique identifier provided by National Health Service (NHS) 
Scotland for each resident registered with a general practice. Public Health Scotland routinely 
adds both maternal and baby CHI numbers to live birth registration records: these ‘spine’ 
records will be used to facilitate intergenerational linkage of records relating to mothers and 
their babies.
An overall schema for the planned linkage is provided in Figure 1. Unless otherwise specified, 
included datasets are held by Public Health Scotland (PHS) and PHS is the data controller.
Datasets to identify pregnant women in the general population and associated pregnancy 
start and end dates, and pregnancy and neonatal outcomes
i) Antenatal booking records: This is a new national data return developed as part of the 
response to the COVID-19 pandemic providing information on all women booking for 
antenatal care with NHS maternity services throughout Scotland. It will be used for 
identification of women with ongoing pregnancies in near real-time. All other records 
identify end of pregnancy events, thus there is a time-lag before records are generated. More 
than 99% of births in Scotland book for antenatal care with NHS maternity services.23
ii) Abortion Act Scotland [AAS] records: These are statutory notifications of termination of 
pregnancy, and will be used to identify all terminations of pregnancy, and including 
terminations of pregnancy indicated by congenital anomaly.24 
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iii) National Records of Scotland (NRS) statutory stillbirth registrations: Scottish legislation 
requires all stillbirths at 24 weeks gestation or more to be registered with NRS.25
iv) NRS statutory live birth registrations: Scottish legislation requires all live births at any 
gestation to be registered with NRS.26
v) NHS Scottish health board live births: A new national data return developed as part of the 
response to the COVID-19 pandemic (specifically to mitigate unavailability of NRS statutory 
live birth registration records when registration processes were suspended) providing 
information on all live births notified by maternity services to NHS Board child health 
administrative departments. 
vi) GP data: Data from all patients registered in general practices are included in the EAVE II 
platform.18 In COPS, these records will be used for identification of women with early 
miscarriage or ectopic pregnancy not managed in hospitals, and potential confounding co-
morbidities.
vii) Scottish Morbidity Record (SMR) 01: The SMR01 database includes all general day case 
and in-patient admissions in Scotland.27 Admissions to neonatal, maternity, and mental health 
care are excluded from SMR01 as they are covered by other specialist datasets.  SMR01 
records are included in the EAVE II platform, and in COPS will be used for identification of 
women with early miscarriage or ectopic pregnancy managed in hospitals, and potential 
confounding co-morbidities. 
viii) SMR 02: The SMR02 database includes all day case and in-patient admissions to 
maternity specialties in Scotland.27 It will be used for identification of later miscarriage, 
stillbirth, and live births managed in maternity units (≥98% of births in Scotland) and some 
home births (≤2% of births in Scotland).23 
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ix) Scottish Birth Record (SBR): The SBR records basic demographic data on all births in 
Scotland, and additional clinical information and diagnostic and operational procedure codes 
on babies admitted to neonatal care.28 It will be used to identify neonates admitted to neonatal 
care. 
x) Scottish Intensive Care Society Audit Group (SICSAG) records: This is a national 
database of patients admitted to adult general critical care units in Scotland detailing 
information on the management of critically ill or injured patients. All general Intensive Care 
Units and combined ICU/High Dependency Units (HDU) collect data and more than 90% of 
general High Dependency Units and a number of specialist ICU and HDUs also provide 
records.29 In COPS these will be used to identify women admitted to critical care with 
COVID-19.
Datasets to identify women with confirmed SARS-CoV-2 infection or COVID-19
i)  Electronic Communication of Surveillance in Scotland (ECOSS)30 and other viral RT-PCR 
and serology results held separately by PHS are included on the EAVE II platform.18 In 
COPS, these will be used for identification of pregnant women and neonates with positive 
viral RT-PCR and serology, and women with negative viral RT-PCR. 
ECOSS is a database that holds surveillance data on various microorganisms (e.g. influenza 
virus, coronavirus) and infections reported from NHS diagnostic and reference laboratories.30 
Data on laboratory results for all SARS-CoV-2 RT-PCR tests carried out in Scotland are 
being collated by ECOSS and can be linked to other data sources.30 
In sub-studies, residual sera from routine antenatal booking blood tests and 28 week gestation 
blood group and red cell antibody screen samples will be tested for SARS-CoV-2 antibodies.  
Residual sera from other blood tests conducted as part of routine (not COVID-19 related) 
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primary and secondary care, and blood donation, are also being tested for SARS-CoV-2 
antibodies as part of the surveillance of the pandemic in Scotland, and any results relating to 
pregnant women will also be incorporated.31  Results from these sub-studies will be linked to 
pregnancy records and used to determine exposure to SARS-CoV-2 by the presence of 
antibodies.18
ii) GP consultations, GP out of hours attendances, NHS24 calls, COVID-19 phone 
assessment hub calls, and COVID-19 clinical assessment centre attendances are linked on the 
EAVE II platform.18 We will extract data on pregnant women with possible COVID-19 from 
GP records and a network of COVID-19 Community Hubs and Assessment Centres 
established by NHS Health Boards across Scotland. These provide a direct and rapid route for 
people with COVID-19 symptoms that have worsened or not improved after a week to seek 
advice and primary care. The pathway for management of patients in the community with 
symptoms suggestive of COVID-19 has evolved as the pandemic has progressed.  In early 
March 2020, patients with symptoms were advised to phone their GP in hours or NHS 24 out 
of hours for advice.  Patients requiring face to face assessment were then seen in GP surgeries 
or GP out of hours centres.  On 17 March 2020, the Scottish Government published details of 
a new national patient pathway, whereby all patients with symptoms (in or out of hours) were 
encouraged call NHS 24 as the initial point of contact.32 Patients thought likely to have 
COVID-19 were then passed to a new, dedicated NHS24 COVID-19 phone assessment hub.  
Those requiring face-to-face assessment in general were then seen in (or visited at home by 
staff from) an NHS24 COVID-19 clinical assessment centre, although pregnant women could 
alternatively be directed to their maternity service triage base.32 
iii) Unscheduled Care Datamart (UCD):  This links data from NHS 24, Scottish Ambulance 
Service, Out of Hours Primary Care, Emergency Department, Acute and Mental Health 
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admissions and Deaths to show a Continuous Unscheduled Care Pathway. Data is included in 
the EAVE II platform.18 In COPS, we will use Scottish Ambulance Service incident and 
A&E attendance records for identification of women with possible COVID-19.33
iv) NRS statutory death registrations will be used for identification of any women with 
COVID-19 recorded as cause of death.34
v) SMR01, SMR02, and NRS stillbirths will be used to identify women with COVID-19 
recorded as cause of admission/stillbirth.25 27
Datasets recording treatments, vaccination, shielding status and inclusion in other studies
i) Prescribing Information System (PIS). This includes information on all prescribed 
medications that are dispensed in the community in Scotland.35 Lookback records are 
included in the EAVE II platform18 and used to provide information on the presence of co-
morbidities. In COPS records will also be used provide information on COVID-19 treatments 
given. 
ii)  Scottish Hospital Electronic Prescribing and Medicines Administration (HEPMA) 
systems are currently available within four Scottish hospitals, and data from these are linked 
in the EAVE II platform18 to provide data on medications for COVID-19 administered in 
hospitals.36
iii) GP consultation records included on the EAVE II platform18 will be used to extract 
information on vaccinations for SARS-CoV-2 and other viruses.
iv) We will identify pregnant women and neonates with COVID-19 in existing enhanced 
surveillance studies using minimal ‘flag’ variables from the BPSU and CO-CIN studies,15-17 
as well as other trials who can provide this data. 
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Exposure and Outcome definitions 
Pregnancy, start and end dates and pregnancy outcomes
A pregnancy will be defined by presence of a record pertaining to a pregnancy. As well as 
identifying completed pregnancies, through a record of any pregnancy outcome, we will be 
able to identify ongoing pregnancies at population level, through inclusion of records from 
women booked for antenatal care. 
The following definitions will be used for pregnancy outcomes. The codes and data sources 
used to identify relevant records, are described in detail in Supplementary material. 
i) Ectopic pregnancy: This will include any early pregnancy loss where the pregnancy is 
implanted outwith the uterus 
ii) Spontaneous pregnancy losses: These will be defined as miscarriage at less than 20 weeks 
gestation, late fetal losses at 20 - 23 weeks if there are no signs of life; and stillbirth if birth 
occurs at 24 weeks’ gestation or more and there are no signs of life. If numbers allow, the 
miscarriages will be further split into the more clinically meaningful outcome categories of 
miscarriage at less than 14 weeks gestation; and miscarriage 14 weeks gestation and beyond. 
iii) Termination of pregnancy: These will be subclassified by the grounds for termination of 
pregnancy of the Abortion Act 1967.37
iv) Live birth: The birth of a baby at any gestation with signs of life. No lower gestational 
limit will be used although in practice around 22 weeks gestation would be considered the 
lower limit at which live born babies may survive
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Pregnancy start date will be taken as the date of conception. In pregnancies that have ended 
date of conception will be imputed from
 “Date of conception = pregnancy end date - (the number of weeks of gestation at pregnancy 
end + 2 weeks)”
In ongoing pregnancies that have booked with maternity services and have a documented 
estimated date of delivery (EDD), date of conception will be imputed from 
“Date of conception = date of antenatal booking – (gestation at booking + 2 week)” 
In ongoing pregnancies without a documented EDD, date of conception will be imputed from 
“Date of conception = date of last menstrual period + 2 weeks”.
It is standard care for women who book with maternity services in Scotland have a first 
trimester ultrasound scan (usually 11-13+6 weeks gestation) to determine EDD, from which 
gestation is calculated. Booking takes place around 10 weeks gestation. 
SARS-CoV-2 infection and COVID-19
We will use the following definitions for COVID-19. 
 Confirmed COVID-19 in pregnancy will be defined as positive viral PCR for SARS-
CoV-2 on a test. 
 Probable COVID-19 will be defined as COVID-19 recorded on a hospital admission, 
stillbirth, or a maternal death record (using ICD10 codes U07.1, U07.2, B34.2, B97.2)
 Possible COVID-19 will be defined as meeting one or more of the following criteria:
o GP consultation or GP out of hours attendance coded as possible COVID-19
o NHS24 call coded as possible COVID-19
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o Patient triaged to NHS24 COVID-19 phone assessment hub or clinical 
assessment centre
o Scottish Ambulance Service call for possible COVID-19
o A&E attendance coded as possible COVID-19
o Negative SARS-CoV-2 viral PCR test when the test was taken for clinical 
indications (i.e. excluding tests taken for routine testing of asymptomatic 
individuals)
The above definitions are hierarchical, e.g. a positive SARS-CoV-2 nucleic acid test assigns a 
woman to the confirmed COVID-19 group, regardless of the presence of other records.
We will use the indication for SARS-CoV-2 nucleic acid test, which is recorded in ECOSS 
records, to distinguish between tests taken for clinical indications and routine testing of 
asymptomatic individuals. If we can’t distinguish between these groups, we will exclude 
women testing negative from both the ‘case’ and ‘control’ groups – and base our definition of 
possible case on presentation to various healthcare settings with relevant symptoms as 
described above.
SARS-CoV-2 infections during pregnancy will be identified if the event of interest (e.g. 
SARS-CoV-2 nucleic acid test taken, admission, unscheduled care attendance) occurs 
between 14 days prior to the estimated date of conception (to include women who could be 
viraemic periconceptually) and the end of pregnancy.
We will seek to access serological data as these become available. We will report the 
proportion of women with circulating IgG and/or IgM for SARS-CoV-2 and may incorporate 
serology results in case definitions and/or use in additional analyses as data mature. The 
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timing of exposure to/infection with SARS-CoV-2 is more difficult to ascertain from 
serology results than from the other indicators of (possible) infection listed above.  Dates of 
serological testing; start and end of pregnancy; and plausible start (and, if applicable, end) of 
transmission of SARS-CoV-2 in Scotland will be taken into account when identifying women 
with exposure before, during, and after pregnancy. Seroconversion windows will also be 
considered for women with sequential serology results.
We have included hierarchical definitions of COVID-19 to mitigate against potential biases 
that may results from i) limitations of diagnostic strategy performance and ii) variation in 
availability of diagnostic tests. The definition of confirmed COVID-19 (women who test 
positive on PCR) may potentially bias results away from the null hypothesis (due to false 
negative PCR results). The definition of possible COVID-19 may potentially bias results 
towards the null hypothesis (due to false positive ‘diagnoses’). We will test our hypotheses in 
this observational cohort across the range of assumptions allowed by hierarchical definitions. 
Other diagnostic and exposure categories may be added as the pandemic develops and 
diagnostic criteria change. 
Fetal and neonatal outcomes
The following fetal and neonatal outcomes will be included.
i) Congenital anomaly (major structural anomaly as defined by EUROCAT 38 diagnosed in 
any pregnancy terminated at any gestation due to anomaly; miscarriage or stillbirth at ≥20 
weeks; or live born baby diagnosed at <28 days of age)
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ii) Preterm birth (<37 weeks) categorised as spontaneous or medically indicated (i.e. 
following induction of labour or elective Caesarean section undertaken to mitigate clinical 
risk)
iii) Small for gestational age (birthweight <10th centile by WHO-UK90 growth reference 39)
iv) Admission to neonatal care
v) Neonatal SARS-CoV-2 infection (currently defined as positive viral RT-PCR test on 
sample taken from baby aged 0-27 days, definition may be expanded to include results of 
serology tests as evidence and testing options accumulate)
vi) Neonatal mortality (death of a live born baby at <28 days of age)
vii) Extended perinatal mortality (stillbirth or neonatal mortality) 
Maternal outcomes
We will collect data on the following maternal outcomes:
 COVID-19 disease requiring any hospital admission (defined as a patient admitted 
within 14 days of confirmed or probable COVID-19, or with confirmed or probable 
COVID-19 during admission)
 Severe COVID-19 disease requiring critical care admission or resulting in death 
(defined as patient admitted to critical care or dying within 28 days of confirmed or 
probable COVID-19, or with confirmed or probable COVID-19 during hospital 
admission, regardless of recorded cause of death)
 Any maternal death (defined as the death of a woman while pregnant or within 42 
days of the termination of pregnancy, irrespective of the duration and site of the 
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pregnancy, from any cause related to or aggravated by the pregnancy or its 
management but not from accidental or incidental causes)
Population characteristics and confounding factors
A number of maternal and pregnancy characteristics will be collected that could be potential 
confounders or effect modifiers. 
i) Demographics including age band and socioeconomic status determined by the Scottish 
Index of Multiple Deprivation (SIMD) classification of material deprivation.40 SIMD 
Quintiles 1 through 5 refer to the small geographical areas (data zones) each containing 20% 
of the Scottish population, with quintile 1 indicating the most deprived areas. The SIMD is a 
combination of 38 indicators of the following seven domains: income, employment, health, 
education, housing, geographical access to services, and crime. We will also include 
urban/rural status of maternal residence based on the urban/rural 8 fold classification (UR8)41 
where 1 is assigned to large urban areas and 8 is assigned to remote rural areas. We recognise 
ethnicity to be a complex indicator variable related to sociodemographic factors, health 
systems use, pregnancy and health outcomes and genetics. We will explore the possibility of 
including self-reported maternal ethnicity although missing data may preclude this.
ii) Clinical at-risk groups of individuals with certain underlying medical conditions thought 
to increase risk of COVID-related complications. The following clinical at-risk conditions are 
identified in the EAVE II platform18: a) chronic respiratory disease; b) chronic heart disease; 
c) chronic liver disease; d) chronic kidney disease; e) chronic liver disease; f) chronic 
neurological disease; g) Diabetes; h) Conditions or medications causing impaired immune 
function; i) Asplenia or dysfunction of spleen and j) body mass index (BMI). In addition, we 
will link pregnancy records with the shielded patient list included in the EAVE II platform 
Page 60 of 93
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
21
(those with extremely high risk of severe manifestation of SARS-CoV-2 infection, and hence 
advised by Scottish Government to ‘shield’ during the pandemic). We will re-categorise 
clinical risks for the pregnant population as i) Diabetes (Type I; Type II; Other pre-
pregnancy; Gestational Diabetes); ii) clinically vulnerable risk group (for whom seasonal 
influenza vaccination is recommended outwith pregnancy);  iii) clinically extremely 
vulnerable risk group ( those advised to ‘shield’ during the pandemic);42 and iv) no clinical 
at-risk condition. BMI, which can be associated with adverse pregnancy outcomes as well as 
COVID-disease will be included separately, with pre-pregnancy BMI or BMI at antenatal 
booking categorised as Underweight, Normal, Overweight, Obese and Severely Obese 
according to WHO definitions.43 Other categorisation will be considered depending on 
numbers of pregnant women with these conditions, and emergence of patterns of risk for 
COVID-19 disease.
iii) Smoking status in pregnancy will be presented into the following four categories: Current 
smoker, non-smoker, ex-smoker and not recorded. Smoking status will be taken from 
booking record and/or GP records.
iv) Obstetric characteristics (SMR02) will include previous pregnancies, plurality (number of 
babies), drug and alcohol use, antenatal steroid administration, mode of birth or management 
of pregnancy loss.
v) Clustering of outcomes by the 14 different Maternal NHS Board areas of residence. 
Statistical analysis
General Approach
Baseline characteristics of all study participants will be described in relation to presence and 
absence of confirmed, probable or possible COVID-19 and outcomes of interest. Mean, median 
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and proportions, together with a measure of dispersion will be provided where appropriate to 
describe differences between the various groups of interest based on the nature of each variable. 
Missing data will be provided for each variable. Two-tailed hypotheses tests will be used for 
all study’s outcomes, with 95% confidence intervals presented to show precision of estimates, 
and p values reported. All analyses will be carried out using the R statistical programming 
language. We do not propose to make any formal statistical adjustment for the multiple 
comparisons as the principal aim of the study is to estimate the effect of COVID-19 infection 
on pregnancy outcomes.   The estimated effects and 95% confidence intervals will be reported 
for the range of outcomes.  However, a caveat will be clearly expressed regarding the dangers 
of over interpreting these data, given the multiple outcomes used, particularly if it transpires 
that conflicting results are obtained from the differing outcome measures. We do not propose 
to make any formal statistical adjustment for the multiple comparisons. However, a caveat will 
be clearly expressed regarding the risks of over interpreting these data, given the multiple 
outcomes used. The approach to imputing estimated date of conception when gestation is 
missing on records indicating pregnancy status is detailed in Supplementary material 1. 
Missing data are otherwise not anticipated to be a substantial problem (and hence imputation 
techniques are not anticipated) but this will be confirmed once initial data extracts are available, 
and our approach to handling missing data will be confirmed prior to analysis.
Analyses will be updated monthly, providing results for sequential months, and also 
information on the cumulative risk of COVID-19 as women progress through their 
pregnancies. Simple smoothing techniques such as rolling averages will be used to facilitate 
presentation and interpretation of findings. We will also present our results as proportions of 
COVID-19 infection, together with confidence intervals based upon the Wilson method.  We 
will describe the temporal changes in the proportion using cumulative risk models.  
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Covariates such as the trimester of pregnancy, age of the mother and deprivation will also be 
included with a view to estimating the potential effects of these variables on the risk of 
COVID-19 infection
If/when numbers of cases allow, we will examine incidence of COVID-19, and report 
outcomes, in subgroups including by maternal age band, SIMD deprivation quintile, maternal 
NHS Board area of residence and maternal comorbidity status. We may assess whether 
findings are robust to more stringent or emerging definitions of confirmed and suspected 
infection, in sensitivity analyses. Other sensitivity and subgroup analyses may be indicated 
by initial findings. We will clearly state which analyses were pre-specified and which were 
post-hoc.
Incidence of SARS-CoV-2 and COVID-19 in the pregnant population 
We will perform descriptive analysis of the number of cases over the total number of 
pregnancies i.e. how many pregnant women have had confirmed, probable or possible 
COVID-19/ total number of pregnant women.  Where timing of infection is known, we will 
describe incidence of SARS-CoV-2 infection by trimester of exposure - first trimester (0-13 
weeks gestation) second trimester (14-27 weeks gestation); third trimester (≥28 weeks 
gestation)44; with denominators consisting of ongoing pregnancies in each trimester. 
Associations between COVID-19 and adverse pregnancy, neonatal and maternal outcomes.
Initially we will perform a descriptive analysis comparing pregnancy outcomes in women 
with and without i) confirmed; ii) probable and iii) possible COVID-19. In order to create 
appropriate comparison groups, for each woman with COVID-19, we will identify ten 
women without COVID-19, with an ongoing pregnancy matched on gestation of diagnosis, 
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and additionally matched on maternal age and maternal deprivation level.  We will explore 
the need to match additional parameters such as NHS Board.
Occurrence of the outcomes of interest will be compared in women with and without 
COVID-19 using simple descriptive statistics (e.g. 95% confidence interval for the difference 
in proportions, generated using methods which accommodate proportions close to zero) and 
visualised appropriately.
If/when sufficient cases of COVID-19 among pregnant women accrue, and the univariable 
comparisons described above suggest that outcomes differ between women with and without 
SARS-2-CoV or COVID-19, formal modelling will be undertaken to quantify the impact of 
infection on outcomes, adjusting appropriately for confounding. We will use direct acyclical 
graphs (DAGs) to identify which factors to adjust for to mitigate for confounding.  
Appropriate methods that accommodate the competing risk and time to event nature of 
pregnancy outcomes (example event history analysis and/or multistate modelling) will be 
used.
Association of SARS-CoV-2 in neonates with maternal COVID-19
We will use summary statistics to describe neonatal SARS-CoV-2 (currently defined as 
positive viral PCR for SARS-CoV-2 on sample taken from a baby aged 0-27 days old) by 
presentation of COVID-19 in the mother in different time periods (apparent onset of maternal 
illness >14 days prior to birth; 14 days prior to birth - date of birth; day 1 - 13 following 
birth; day 14 - 27 following birth). 
Proportion of pregnant women and neonates with COVID-19 or SARS-CoV-2 that are 
included in relevant other enhanced surveillance studies (BPSU, CO-CIN)
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We will use summary statistics to describe the number and proportion of cases included in 
the external surveillance studies, and any factors associated with inclusion e.g. hospital 
admission status and NHS Board area of residence.
Creation of a platform to assess the safety and effectiveness of any new or existing 
prophylactic or therapeutic interventions and assessment of childhood outcomes after 
pregnancy exposure to COVID-19
We will use summary statistics to describe the treatments and prophylactic interventions used 
in pregnancy. We plan future linkage of data within COPS with child health and education 
data to allow assessment of long-term outcomes. 
Sample size
There are approximately 50,000 live births in Scotland per year, 13,000 terminations of 
pregnancy, 5,000 miscarriages managed in hospital and 200 stillbirths.  The estimated 
number of women in the population who are pregnant at any one time is approximately 
42,000.
We cannot influence the number of women with confirmed, probable or possible COVID-19 
available for analysis hence sample size calculations will not be performed.  We will report 
the precision with which we are able to estimate any association between COVID-19 and the 
outcomes of interest using confidence intervals as appropriate. An approximate estimate of 
the expected number of confirmed COVID-19 cases in pregnant women from March to May 
2020 is presented in Table 2. It is likely that there will be further confirmed or probable cases 
in pregnant women identified through PCR testing processed through UK Government 
laboratories and clinical diagnoses on discharge (or possibly stillbirth or maternal death) 
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records. In addition, it is likely that there will be considerably more possible cases among 
pregnant women based on the range of data sources listed above. 
ETHICS AND DISSEMINATION 
COPS is a sub-study of EAVE II, using unconsented data, which is covered by National 
Research Ethics Service Committee, South East Scotland 02 approval reference REC 
12/SS/0201: SA 21 and Public Benefit and Privacy Panel approval reference 2021-01161920-
0279. Public Health Scotland and the Chief Medical Officer for Scotland are both 
(independent) data controllers for the national AAS database of termination of pregnancy 
notifications, thus the Chief Medical Officer has been informed of the intended use of AAS 
records for this study.
The results of monthly analyses summarising the incidence of COVID-19 in pregnant 
women, and outcomes seen in women with COVID-19 and pregnant controls, will be 
reported through the Public Health Scotland COVID-19 enhanced surveillance cell to the 
Scottish Government’s Chief Medical Officer’s COVID-19 Advisory Group.  Any results of 
formal modelling of outcomes that is undertaken will be reported through the same route.  
Results reported through this route may be provided as management information (i.e. without 
application of statistical disclosure control restrictions) as appropriate.
Results will also be submitted for peer reviewed academic publication and presented at 
international conferences.  All results put into the public domain will be subject to statistical 
disclosure control according to usual Public Health Scotland processes. Meta-data produced 
in this study will also become available to Health Data Research UK (HDRUK) Gateway. 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
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guidance454 and Reporting of studies Conducted using Observational Routinely-collected 
Data (RECORD) guidance465 will be used to guide transparent reporting.
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TABLES
Table 1: UK surveillance studies on COVID-19 in pregnant women and their babies
Name of study Institution Inclusion Reporting by Consent 
required
Likely 
coverage 
in 
Scotland
COVID-19 in 
Pregnancy 476
UK Obstetric 
Surveillance 
System study
(UKOSS) 
Any women 
admitted to 
hospital in the 
UK with 
confirmed 
COVID-19 at 
any stage of 
pregnancy
Front-line 
clinicians 
No High
Pregnancy And 
Neonatal 
outcomes for 
women with 
COVID-19 
(PAN-COVID) 
487
National 
Institute of 
Healthcare 
Research 
(NIHR) 
Imperial 
Biomedical 
Research 
Centre 
Women who 
have suspected 
or confirmed 
COVID-19 at 
any stage 
during 
pregnancy and 
their babies
Front-line 
clinicians
Yes Unknown 
as yet
Clinical 
Characterisation 
Protocol Tier 0 
The 
International 
Severe Acute 
Any patient 
admitted 
participating 
Reporting is by 
research nurses
No Low but 
may 
increase
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study (CO-CIN) 
17
Respiratory 
and 
emerging 
Infection 
Consortium 
(IASRIC)
hospitals in the 
UK with 
confirmed 
COVID-19
Neonatal 
complications of 
coronavirus 
disease 
(COVID-19) 17
British 
Paediatric 
Surveillance 
Unit (BPSU) 
All babies 
born to 
mothers with 
COVID-19 
who are 
admitted to 
neonatal care 
(whether the 
baby has 
COVID-19 or 
not) and all 
babies with 
confirmed 
COVID-19 in 
the neonatal 
period.
Front-line 
clinicians.  
No High
Multisystem 
inflammatory 
syndrome, 
Kawasaki 
disease and toxic 
British 
Paediatric 
Surveillance 
Unit (BPSU) 
All children 
less than 16 
years old 
(including 
neonates) with 
Front-line 
clinicians  
No High
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38
shock 
syndrome15
multisystem 
inflammatory 
syndrome due 
to SARS-CoV-
2 infection or 
otherwise 
unexplained. 
Understanding 
COVID-19 
infection in 
women and their 
babies 
(periCOVID)498
Public 
Health 
England and 
St George’s 
University 
London
Any pregnant 
woman with 
confirmed 
COVID-19 
infection from 
24 weeks 
gestation in 
England
Clinicians/research 
midwives and 
nurses
Yes None
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Table 2: Estimated number of confirmed COVID-19 cases March to May 2020 in 
pregnant women in Scotland
Total number of 
individuals testing 
positive (PCR) for 
SARS-CoV-2 (NHS 
labs only)
Women aged 15-44 
years testing 
positive (PCR) for 
SARS-CoV-2 (NHS 
labs only)
Estimated number of 
pregnant women 
testing positive 
(PCR) for SARS-
CoV-2 (NHS labs 
only)**
March 2020 ≈2000 ≈333* ≈17
April 2020 ≈9000 ≈1500* ≈75
May 2020 ≈4000 ≈667* ≈33
Total ≈15000 ≈2500 ≈125
* Assuming the distribution over time for this age/sex group is the same as for all tests,
as age/sex breakdown only available from published information49 50 for the total
** Assuming that around 5% of the female population aged 15-44 is pregnant at any one 
time, and that incidence of COVID-19 is the same in pregnant and non-pregnant women
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FIGURE LEGENDS
Figure 1: Overview of data linkage for the Covid-19 in Pregnancy in Scotland (COPS) study
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Figure 1: Overview of data linkage for the Covid-19 in Pregnancy in Scotland (COPS) study
Identify cohort of women in Scotland
pregnant at any time from 1 March 2020 onwards
Continuing pregnancy
Antenatal booking data
Ended pregnancy
GP consultation data, SMR01, AAS, SMR02
NRS stillbirths, NRS and NHS live births
Confirmed Probable Possible
ECOSS + SMR01 GP consultations and GP out of hours contacts
SMR02 NHS24 111 and Covid19 telephone triage calls
NRS stillbirths Covid-19 community assessment centre contacts
NRS deaths Scottish Ambulance Service
A&E
ECOSS +
SARS-CoV-2 serology results may also be examined, and incorporated into case definitions as appropriate
Identify maternal outcomes Identify pregnancy outcomes Identify baby's outcomes
SMR01 GP consultation data AAS
SMR02 SMR01 SMR02
SICSAG AAS NRS stillbirths
NRS deaths SMR02 Scottish Birth Record
NRS stillbirths SMR01
NRS live births NRS deaths
NHS live births ECOSS +
Intergenerational linkage 
through NRS and NHS live birth records
Information on confounders and comorbidities Information on inclusion of study members
(and vaccination or treatment for Covid-19 if relevant) in other Covid-19 enhanced surveillance studies
GP consultation data BPSU Covid-19 in neonates
SMR01 BPSU MIS
SMR02 CO-CIN
Shielded patient list
PIS
HEPMA
Identify women in cohort with Covid-19
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Supplementary Material: Additional information on identifying pregnant women, and associated start and end of pregnancy dates, 
from national data sources 
 
National data sources identifying end of pregnancy events 
 
There are three possible outcomes for any pregnancy 
Pregnancy outcome Comments 
Spontaneous loss ‘Miscarriage’ at <24w (here taken to include ectopic pregnancies, although 
mechanisms underlying spontaneous miscarriage and ectopic pregnancy differ) 
(Sometime ‘late fetal loss’ at 20-23w as a subset of miscarriages) 
‘Stillbirth’ at ≥24w 
Termination of pregnancy Legal at <24w under Grounds C and D of the Abortion Act 1967 
Legal at any gestation under Grounds A, B, E, F, G 
Live birth No lower gestational limit although in practice around 22w would be considered the 
lower limit at which live born babies may survive 
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Various national records may be returned following these end of pregnancy events, as summarised below 
National record Description Pregnancy outcomes identified Coding to identify relevant records 
Identifying spontaneous pregnancy losses 
SMR01 Record of day case or inpatient 
admission to any general unit 
(excluding neonatal, maternity, and 
mental health care), including 
admissions under gynaecology 
specialty 
Will identify early (first trimester) 
spontaneous losses managed in 
hospital in most Board areas 
ICD10: 
O00 (ectopic pregnancy) 
O01 (hydatidiform mole) 
O02 (missed miscarriage) 
O03, O05, O06 (spontaneous 
miscarriage), all .5-.9 
OR 
SMR02 
Record of day case or inpatient 
admission to a maternity unit, including 
admissions under obstetrics or 
midwifery specialties 
Will identify early (first trimester) 
spontaneous losses managed in 
hospital in some Board areas 
Will identify later (second and third 
trimester) spontaneous losses 
managed in hospital in all areas 
Miscarriages 
Condition on discharge=2 (aborted) 
Type of abortion=1, 2, 3, 6, 8, 9 
(spontaneous) 
 
Stillbirths 
Condition on discharge=3 (delivered) 
Outcome of pregnancy=2 (stillbirth) 
AND/OR 
NRS stillbirths 
Record of statutory registration of a 
stillbirth (baby born at ≥24w showing no 
signs of life) 
Will identify spontaneous stillbirths ICD10: 
P96.4 not recorded 
Identifying terminations of pregnancy 
AAS Record of statutory notification of a 
termination of pregnancy 
Should identify all terminations of 
pregnancy but known under-notification 
of later ToPs done for fetal anomaly 
from some maternity units 
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AND/OR 
SMR02 
As above Will identify later ToPs done for fetal 
anomaly in maternity units 
Condition on discharge=2 (aborted) 
Type of abortion=4 (ToP) 
AND/OR 
NRS stillbirths 
As above Will identify the small number of 
stillbirths following a termination of 
pregnancy 
ICD10: 
P96.4 recorded in any position 
Identifying live births 
SMR02 As above Will identify live births occurring in 
hospital 
SMR02 returns were enabled to cover 
home (as well as in hospital) births from 
Apr 2019, and coverage of home births 
should have been mandatory from Oct 
2019, however technical difficulties 
mean that home births are still (as at 
July 2020) not recorded on SMR02 in 
most Boards 
Condition on discharge=3 (delivered) 
Outcome of pregnancy=1, 3, 4, 5 (live 
birth) 
AND/OR 
NRS live births 
Record of statutory registration of a live 
birth (live born baby at any gestation) 
Usually identifies all live births however 
statutory registration of live births was 
suspended from 23 March to 28 June 
2020 inclusive when registrar offices 
closed 
The only babies being registered during 
that period were those that 
subsequently die: this was done 
remotely along with the death 
registration to avoid parents having to 
register the birth in person later 
A catch up programme of live birth 
registrations started on 29 June 2020 
 
Page 84 of 93
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
AND/OR 
NHS live birth 
notifications 
Notification of live births from NHS 
Board maternity units to child health 
administration departments 
This notification allows a record to be 
created for the child on the national 
child health information system: this in 
turn ensures the child is called for 
immunisations and child health reviews 
As NRS live birth registration was 
suspended in March – June 2020 due 
to COVID-19 (see above), PHS has 
recently developed a new data 
extraction from the national child health 
information system of birth notification 
data 
This will identify all live births known to 
NHS maternity services from Aug 2019 
onwards 
A small number of babies who die very 
soon after birth (before that day’s 
notification data has been sent) will not 
be included as these babies do not 
need to be notified for ongoing care, 
however they will be covered by NRS 
registration as noted above 
 
 
It is possible that the same woman/pregnancy may have multiple records giving conflicting information on the outcome of the pregnancy. 
In general, if any record indicates a termination of pregnancy, this should be taken as the outcome. 
If an NRS stillbirth record is available for a baby but the corresponding SMR02 record indicates the baby was live born, this should be taken as 
a stillbirth. 
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The relevant gestation and date of event information in the various records, and how to deal with missing gestation information, is summarised 
below 
National record Gestation information available Date of event information available Dealing with missing gestation 
information (due to not recorded on that 
record, missing, or recorded but 
unfeasible) 
SMR01 None Date of admission 
Date of discharge 
Assume 12 weeks gestation at date of 
admission 
SMR02 Gestation in completed weeks at end of 
pregnancy available on records where 
Condition on discharge=2 or 3 (aborted 
or delivered) 
Date of admission 
Date of discharge 
Date of delivery on records where 
Condition on discharge=3 (delivered) 
Miscarriage records with missing 
gestation, assume 12 weeks gestation 
at date of admission 
ToP records with missing gestation 
(and not available from AAS), assume 
16 weeks gestation at date of 
admission 
Stillbirth delivery records with missing 
gestation (and not available from NRS), 
assume 32 weeks gestation at date of 
delivery 
Live birth delivery records with missing 
gestation, assume 40 weeks gestation 
at date of delivery 
NRS stillbirths Gestation in completed weeks at date 
of stillbirth available 
Date of stillbirth Assume 32 weeks gestation at date of 
delivery (if not available from SMR02) 
AAS Gestation in completed weeks at date 
of termination available 
Date of termination (date of 
administration of antiprogesterone for 
medical ToPs) 
Assume 10 weeks gestation at date of 
termination (if not available from 
SMR02) 
NRS live births None Date of birth Assume 40 weeks gestation at date of 
birth (if not available from SMR02) 
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NHS live birth 
notifications 
Gestation in completed weeks at date 
of birth available 
(Although note this data has not been 
used before by PHS so will require 
checking before use) 
Date of birth Assume 40 weeks gestation at date of 
birth (if not available from SMR02) 
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The time lag inherent in the different data returns is summarised below 
National record Time lag inherent in data source 
SMR01 Records should be returned to PHS within 6 weeks of patient’s discharge (in practice sometimes longer) 
Monthly batches (all records received to that point) are then uploaded to the analysis platform (SMRA) 
around the middle of each month 
Records are CHI seeded as they are uploaded to the analysis platform (and CHI seeding is refreshed 
monthly thereafter to pick up any previously unseeded records) 
CHI seeding usually complete on first attempt 
So: records relating to discharges in Jan XX should be available for linkage and analysis within PHS in mid 
Apr XX (2.5 month lag) 
SMR02 Records should be returned to PHS within 6 weeks of patient’s discharge (in practice sometimes longer) 
Monthly batches (all records received to that point) are then uploaded to the analysis platform around the 
middle of each month 
Records are CHI seeded as they are uploaded to the analysis platform (and CHI seeding is refreshed 
monthly thereafter to pick up any previously unseeded records) 
Maternal CHI seeding usually complete on first attempt 
Baby CHI seeding usually complete on second attempt 
So: as linkage of SMR02 records is generally through maternal CHI, records relating to discharges in Jan XX 
should be available for linkage and analysis within PHS in mid Apr XX (2.5 month lag) 
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NRS stillbirths Registration required within 21 days of birth 
Data transferred by NRS to PHS weekly 
Monthly batches (stillbirths registered up to the end of the previous month) are then uploaded to the analysis 
platform around the middle of each month 
In parallel, records are sent to NHSCR monthly for seeding of maternal CHI 
As seeded records are returned from NHSCR, the CHIs are added to the records on the analysis platform 
So: records relating to stillbirths occurring in Jan XX should be available for linkage and analysis within PHS 
in mid May XX (3.5 month lag) 
(Note: almost all stillbirths will have an SMR02 record so can be identified and linked with 2.5 month lag) 
AAS Notification to CMO required within 7 days of termination 
Records forwarded to PHS and entered into AAS system (includes automated CHI seeding) within 6 weeks 
of date of termination 
So: records relating to terminations occurring in Jan XX should be available for linkage and analysis within 
PHS in mid Mar XX (1.5 month lag) 
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NRS live births Registration required within 21 days of birth 
Data transferred by NRS to PHS weekly 
Monthly batches (live births registered up to the end of the previous month) are then uploaded to the analysis 
platform around the middle of each month 
Records are seeded with baby CHI as they are uploaded to the analysis platform (and CHI seeding is 
refreshed monthly thereafter to pick up any previously unseeded records) 
Baby CHI seeding usually complete on second attempt 
In parallel, monthly batches are seeded with the mother’s CHI by bespoke linkage to SMR02 after a 6 month 
lag (i.e. records for births in Jan XX and matched against SMR02 in Jul XX) 
Records with no maternal CHI found are then matched against the full CHI database 
Residual records with still no maternal CHI are then sent to NHSCR in monthly batches 
So: as linkage of NRS live birth records generally requires both maternal and baby CHI (to allow 
intergenerational linkage), records relating to births in Jan XX should be available for linkage and analysis 
within PHS in mid Oct XX (8.5 month lag) 
(Note: all live births from Aug 2019 onwards will have a birth notification record available so can be identified 
and linked with a 1 month lag) 
NHS live birth notifications Live births are notified to the NHS Board child health admin department within 1 working day of date of birth 
and are keyed into the national child health info system promptly (same or subsequent day) 
PHS extracts notification data (including baby’s CHI) from the national child health info system weekly 
Maternal CHI is then seeded onto the data extracts weekly 
So: records relating to births in Jan XX should be available for linkage and analysis within PHS in Feb XX (1 
month lag) 
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National data sources identifying continuing pregnancies as early as possible 
 
As part of the response to COVID-19, PHS has established a new national data return providing information on women booking for antenatal 
care.  This will allow us to identify pregnant women before the end of their pregnancy, and hence monitor SARS-CoV-2 infections occurring in 
pregnant women in closer to real time.  Further information on this data source is provided below. 
 
Data items being requested in the new data feed include 
• Maternal CHI 
• Mother’s Forename, Surname, Date of Bi th, and Postcode in case CHI is missing and needs to be appended 
• Date of Booking 
• Gestation at booking 
• Date of Last Menstrual Period (in case gestation is missing) 
 
PHS has asked NHS Boards to provide an initial submission of historic data on all women booking from 1 April 2019, then subsequent weekly 
updates.  The weekly updates will give information on women who have booked in the most recent week, and also update any records relating 
to the previous 2 weeks if those have changed since the previous submission.  The current assumption is that this data will be submitted with 
maternal CHI complete, hence additional lag for CHI seeding will not be required but this is being kept under review. 
 
This dataset will identify all women booking for NHS antenatal care.  The method of providing booking services has changed in many areas due 
to COVID-19, with many Boards now providing the initial booking appointment remotely, with the woman subsequently attending in person for 
her initial ultrasound scan and blood tests1.  To ensure that the dataset allows us to identify pregnant women as early as possible in their 
maternity care journey, the ‘booking’ event that is captured in the above dataset has therefore been defined as ‘the date on which maternity 
services had the first planned/structured contact with a pregnant woman to assess her history and needs so that local maternity services can 
provide further care such as an early pregnancy scan and antenatal screening tests’, i.e. the initial remote contact. 
 
                                                             
1 https://tec.scot/clinical-specialty-guidance/ 
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Available national data shows that, pre-COVID-19, at least 90% of pregnant woman attended their booking appointment by 12+6 weeks 
gestation2.  There is currently no evidence that gestation at initial booking has increased due to COVID-19.  If gestation and LMP are both 
missing on antenatal booking records, we will therefore assume the woman was at 12 weeks gestation at the date of booking. 
 
                                                             
2 https://www.isdscotland.org/Health-Topics/Maternity-and-Births/Publications/ 
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Defining start and end date of pregnancies 
 
For pregnancies that have ended 
Pregnancy end dates will be taken from end of pregnancy records as noted above 
Pregnancy start date (date of conception) will be imputed from the pregnancy end date and the gestation at pregnancy end – 2 weeks 
 
For continuing pregnancies 
Pregnancy start date (date of conception) will be imputed from the date of antenatal booking and the gestation at booking – 2 weeks, or from 
the date of last menstrual period + 2 weeks if gestation is missing and LMP is provided 
 
 
Time lags inherent in data sources identifying COVID-19 status and relevant outcomes 
 
In general, the time lags inherent in data sources identifying COVID-19 status and relevant outcomes are less than (or at least no more than) 
those inherent in the various data sources required to identify pregnancy status. 
The only additional lag that needs to be considered is that seen in Scottish Birth Record (SBR) records.  SBR records are not returned to PHS 
as such.  Rather, PHS takes a monthly download of data held on the system for analysis purposes.  In most NHS Boards, the SBR system is 
used to generate a CHI number for a baby shortly after birth.  Skeleton records with minimal demographic data are therefore available for all 
babies in a timely manner.  For babies admitted to neonatal care, clinical coding staff within NHS Board admin departments are responsible for 
completing additional variables within a baby’s SBR record following their discharge.  There is no national standard for when this should be 
done and in practice the lag between discharge and a completed record being available varies between Boards.  Some Boards achieve broadly 
complete records within 3 months whereas others take considerably longer.  Currently (June 2020) NHS Borders and NHS Dumfries & 
Galloway have not coded any SBR records (or provided comparable data directly to PHS) since June 2017 and April 2018 respectively.  SBR 
data is therefore unlikely to provide a complete picture of neonatal admissions within the timeframes set out for this analysis (i.e. for babies 
born in March 2020, the data available to PHS on SBR by July 2020 will only provide a partial picture of admissions to neonatal care).  PHS 
may explore getting a new national feed from NHS Boards of more real time data on neonatal admissions to mitigate this problem if feasible. 
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Note from the Editors: Instructions for reviewers of study protocols
Since launching in 2011, BMJ Open has published study protocols for planned or ongoing research 
studies. If data collection is complete, we will not consider the manuscript.
Publishing study protocols enables researchers and funding bodies to stay up to date in their fields 
by providing exposure to research activity that may not otherwise be widely publicised. This can help 
prevent unnecessary duplication of work and will hopefully enable collaboration. Publishing 
protocols in full also makes available more information than is currently required by trial registries 
and increases transparency, making it easier for others (editors, reviewers and readers) to see and 
understand any deviations from the protocol that occur during the conduct of the study.
The scientific integrity and the credibility of the study data depend substantially on the study design 
and methodology, which is why the study protocol requires a thorough peer-review. 
BMJ Open will consider for publication protocols for any study design, including observational 
studies and systematic reviews.
Some things to keep in mind when reviewing the study protocol: 
 Protocol papers should report planned or ongoing studies. The dates of the study should be 
included in the manuscript. 
 Unfortunately we are unable to customize the reviewer report form for study protocols. As 
such, some of the items (i.e., those pertaining to results) on the form should be scored as 
Not Applicable (N/A).
 While some baseline data can be presented, there should be no results or conclusions 
present in the study protocol. 
 For studies that are ongoing, it is generally the case that very few changes can be made to 
the methodology. As such, requests for revisions are generally clarifications for the rationale 
or details relating to the methods. If there is a major flaw in the study that would prevent a 
sound interpretation of the data, we would expect the study protocol to be rejected. 
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